This post was originally published on this site A Phase 2 clinical trial assessing Solasia Pharma’s lead candidate darinaparsin as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL) in Asian patients has reached its target enrollment, the company announced. The Asian multinational study (NCT02653976) has recruited 67 patients across 24 sites in Japan,…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Imfinzi Lessens Cancer Spread, Explaining Extended Survival in NSCLC Patients, Phase 3 Data Show
This post was originally published on this site AstraZeneca‘s Imfinzi (durvalumab) decreases the spread of cancer to other parts of the body, explaining the enhanced survival in patients with stage 3 inoperable non-small-cell lung cancer (NSCLC), according to a new analysis of Phase 3 data. This analysis of survival data was gathered from the Phase 3…
Radiotherapy Plans Based on Machine Learning Being Used to Treat Localized PC Patients
This post was originally published on this site Radiotherapy plans generated with machine learning in the RayStation system are now being used at the Princess Margaret Cancer Centre, in Canada, to treat men with localized prostate cancer. RayStation is a treatment planning system (TPS) to optimize care for cancer patients. It combines features such as…
Ovarian Cancer Research Led By David Alberts Given Boost By $5M Memorial Gift
This post was originally published on this site The search for a cure for ovarian cancer has been given a boost by a $5 million gift that will support the clinical research of David S. Alberts, MD, an expert in the field of ovarian cancer research and treatment at the University of Arizona (UA) College…
Multiple Myeloma Patients Best Treated at Recognized Care Centers with High Volume, US Study Reports
This post was originally published on this site Multiple myeloma patients treated in their community by local oncologists have poorer survival outcomes than those receiving care at centers that see large numbers of patients or are nationally recognized, and likely to have doctors with more experience in this disease, a study reports. Its findings were…
Depression and Anxiety May Worsen Quality of Life, Lung Function of Patients with Pulmonary Sarcoidosis, Study Says
This post was originally published on this site Depression and anxiety may worsen the quality of life and lung function of patients with pulmonary sarcoidosis, a study has found. The findings of the study, “Psychological burden associated with worse clinical outcomes in sarcoidosis,” were published in the journal BMJ Open Respiratory Research. Statistics indicate that…
Healing Through Feeling: Cancer and Mental Health
This post was originally published on this site Cancer scars our insides and outsides, but it’s hard to know which it affects more. Cancer affects the body, but the impact of treatment — from chemotherapy to radiotherapy to immunotherapy to stem cell transplants — is highly psychological. My body is slowly healing, but the hardest…
Trastuzumab Deruxtecan Gets FDA Priority Review for Metastatic HER2-Positive Breast Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted priority review to the application seeking trastuzumab deruxtecan‘s (DS-8201) approval for the treatment of metastatic HER2-positive breast cancer. The agency has set a Prescription Drug User Fee Act action date for the second quarter of 2020. By then,…
NICE Favors Adding Rubraca to NHS England to Treat Relapsed Ovarian Cancer
This post was originally published on this site The U.K.’s National Institute for Health and Care Excellence, widely known as NICE, is recommending that Clovis Oncology‘s Rubraca (rucaparib) be available as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube and peritoneal cancer who responded to platinum-based chemotherapy, regardless of their BRCA status or previous…
Xpovio Leads to Promising Responses in Heavily Treated Multiple Myeloma Patients, Phase 2 Trial Shows
This post was originally published on this site Taking Xpovio (selinexor) in combination with the steroid dexamethasone leads to promising responses in heavily treated patients with relapsed or refractory multiple myeloma, a Phase 2 trial shows. The trial’s findings were reported in “Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma,” a study published in the New…
HIV-positive, Non-Hodgkin’s Lymphoma Patients Should Receive Chemotherapy Along with Antiretrovirals Therapy, Retrospective Study Says
This post was originally published on this site People with non-Hodgkin’s lymphoma who are HIV-positive and have not received antiretroviral therapy — a treatment that stops HIV from replicating — have similar outcomes on standard R-CHOP chemotherapy, compared to those who have already started their HIV treatment, a retrospective study found. The study suggests that HIV-positive…
First Patients Dosed in Phase 1/2 Trial Testing Galinpepimut-S, Keytruda Combo in Advanced Cancers
This post was originally published on this site A Phase 1/2 clinical trial assessing the cancer vaccine galinpepimut-S in combination with Keytruda (pembrolizumab) as a treatment for WT-1-positive advanced cancers has started dosing patients, Sellas Life Sciences announced. Galinpepimut-S is a cancer vaccine developed by Sellas to target the Wilms tumor 1 (WT1) protein. WT1…